Takeda Quarterly Profit Weakens, Backs Annual Guidance
By Kosaku Narioka
Takeda Pharmaceutical reported a drop in first-quarter net profit but kept its annual earnings forecasts unchanged.
The Japanese drugmaker said Thursday that net profit fell 8.9% from a year earlier to 113.20 billion yen, equivalent to $692.7 million, for the three months ended June. That beat the estimate of Y85.3 billion in a poll of analysts by data provider Visible Alpha.
First-quarter revenue grew 10% to Y1.220 trillion. The bottom line was weighed by higher tax expenses as well as increases in research and development and selling, general and administrative expenses.
For the fiscal year ending March 2027, the company reiterated expectations for a 3.0% rise in revenue to Y4.640 trillion and net profit of Y166.00 billion, compared with a net loss the previous year.
First-quarter sales of ulcerative colitis drug Entyvio rose 15% to Y268.3 billion, while sales of plasma-derived products climbed 8.8% to Y283.9 billion.
Write to Kosaku Narioka at kosaku.narioka@wsj.com
(END) Dow Jones Newswires
July 30, 2026 03:14 ET (07:14 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States